Rockville, MD – April 24, 2017 – MockV Solutions, Inc. (MockV or the Company), a biotechnology company developing non-infectious viral clearance prediction products that address the unmet needs of process development scientists as they establish biopharmaceutical manufacturing platforms, announced today that it is partnering with Texcell North America, Inc. (Texcell N.A.) to assess its Mock Virus Particle (MVP) technology. The assessment will be conducted at Texcell N.A.’s headquarters in Frederick, Maryland and is designed to compare the removal of MockV’s non-infectious MVM-MVP’s to live Minute Virus of Mice (MVM) through a series of nanofiltration experiments.
Minute Virus of Mice (MVM), a small and physicochemical resistant parvovirus, is a universal standard for assessing viral clearance during process validation studies. Currently, assessments are made by spiking live infectious MVM into biopharmaceutical material, processing the material through a scaled down version of a manufacturing process step, quantifying MVM before and after processing and determining the removal efficiency of the challenged process step. To help facilitate the attainment of knowledge during bioprocess development, both Texcell and MockV are trying to provide novel solutions. MockV, through the pursuit of non-infectious MVP Kits and Texcell, through the offering of investigational studies which are quick and cost effective.
“This study will help determine if MVM-MVP’s can accurately predict live MVM clearance through side by side MVM-MVP/live MVM spiking experiments”, said MockV Founder and CEO David Cetlin. “We are excited to see our MVP’s in action and anticipate the publication and presentation of our findings with Texcell as soon as data is available.” “Our organization is also very excited to work with MockV to develop novel MVP methods that will potentially shorten critical timelines for biotherapeutic process development” stated Dr. Luke Pallansch, Scientific Director at Texcell – North America. “I believe this novel technology will be a powerful tool for Process Developers in the future and we look forward to demonstrating its feasibility in this regard.”